Chemical Biology & Drug Design · 2015 · 18 citations · 26 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructure-activity RelationshipsAntineoplastic Drug ClassesLead Compound DesignOncology PharmacologyAnticancer ActivityAnticancer Compound ScreeningCytotoxicity AssaysMedicinal HeterocyclesSingle-crystal DiffractionSingle-crystal X-ray DiffractionStereochemical Structure - Activity RelationshipStructure - Activity Relationship Optimization
A series of (E,Z)-1-(dihydrobenzofuran-5-yl)-3-phenyl-2-(1,2,4-triazol-1-yl)-2-propen-1-ones (C1-C35) were designed and synthesized, and the structures of compounds (Z)-C27 and (Z)-C29 were confirmed by single-crystal X-ray diffraction. The antitumor activities of these novel compounds against cervical cancer (HeLa), lung cancer (A549), and breast cancer (MCF-7) cell lines were evaluated in vitro. Majority of the title compounds exhibited strong antitumor activities and were much more promising than the positive control Taxol, which were also accompanied by lower cytotoxicity to normal cells. In particular, compounds (E,Z)-C24 exhibited the most consistent potent activities against three neoplastic cells with IC50 values ranging from 3.2 to 7.1 μm. Further researches demonstrated that compounds (E,Z)-C24 could induce cell apoptosis and arrest cell cycle at the G2/M and S phases. Meanwhile, the structure-activity relationship between the configurations and cytotoxicity of the compounds was also investigated.
26
Luc Pieters, Stefaan Van Dyck, Mei Guo Gao et al. · Journal of Medicinal Chemistry · 1999 · 204 citations · Full text
Highly Potent Triazole-Based Tubulin Polymerization Inhibitors
Qiang Zhang, Youyi Peng, Xin Wang et al. · Journal of Medicinal Chemistry · 2007 · 157 citations · Full text